156 related articles for article (PubMed ID: 23009178)
1. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Zhu J; Wang Y; Duan J; Bai H; Wang Z; Wei L; Zhao J; Zhuo M; Wang S; Yang L; An T; Wu M; Wang J
J Exp Clin Cancer Res; 2012 Sep; 31(1):80. PubMed ID: 23009178
[TBL] [Abstract][Full Text] [Related]
2. EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.
Que D; Xiao H; Zhao B; Zhang X; Wang Q; Xiao H; Wang G
Cancer Biol Ther; 2016; 17(3):320-7. PubMed ID: 26785777
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
Griffiths EA; Gore SD; Hooker C; McDevitt MA; Karp JE; Smith BD; Mohammad HP; Ye Y; Herman JG; Carraway HE
Leuk Lymphoma; 2010 Sep; 51(9):1711-9. PubMed ID: 20795789
[TBL] [Abstract][Full Text] [Related]
4. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
5. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
7. Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression.
Jin Z; Zhao C; Han X; Han Y
BMC Cancer; 2012 Oct; 12():480. PubMed ID: 23075330
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway.
Xie Q; Chen L; Shan X; Shan X; Tang J; Zhou F; Chen Q; Quan H; Nie D; Zhang W; Huang AL; Tang N
Int J Cancer; 2014 Aug; 135(3):635-46. PubMed ID: 24374650
[TBL] [Abstract][Full Text] [Related]
9. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
10. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome.
Wang H; Fan R; Wang XQ; Wu DP; Lin GW; Xu Y; Li WY
Ann Hematol; 2013 Jan; 92(2):199-209. PubMed ID: 23093371
[TBL] [Abstract][Full Text] [Related]
11. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
12. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.
Song J; Shi J; Dong D; Fang M; Zhong W; Wang K; Wu N; Huang Y; Liu Z; Cheng Y; Gan Y; Zhou Y; Zhou P; Chen B; Liang C; Liu Z; Li W; Tian J
Clin Cancer Res; 2018 Aug; 24(15):3583-3592. PubMed ID: 29563137
[No Abstract] [Full Text] [Related]
13. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
14. Methylation analysis of SFRP genes family in cervical adenocarcinoma.
Lin YW; Chung MT; Lai HC; De Yan M; Shih YL; Chang CC; Yu MH
J Cancer Res Clin Oncol; 2009 Dec; 135(12):1665-74. PubMed ID: 19513747
[TBL] [Abstract][Full Text] [Related]
15. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
[TBL] [Abstract][Full Text] [Related]
16. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.
Sun JM; Rampal S; Lee G; Lee J; Choi YL; Parasuraman B; Guallar E; Cho J; Shim YM
Lung Cancer; 2013 May; 80(2):191-6. PubMed ID: 23384673
[TBL] [Abstract][Full Text] [Related]
17. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
Bai H; Wang Z; Chen K; Zhao J; Lee JJ; Wang S; Zhou Q; Zhuo M; Mao L; An T; Duan J; Yang L; Wu M; Liang Z; Wang Y; Kang X; Wang J
J Clin Oncol; 2012 Sep; 30(25):3077-83. PubMed ID: 22826274
[TBL] [Abstract][Full Text] [Related]
18. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
19. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.
Wang F; Wang S; Wang Z; Duan J; An T; Zhao J; Bai H; Wang J;
J Exp Clin Cancer Res; 2012 Aug; 31(1):65. PubMed ID: 22901364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
